Evidence map›Paper›PMID 24358807›Full record

ArticleF1000Research2012

Innate B cells: oxymoron or validated concept?

Carl F Ware, Chris Benedict

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in F1000Research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Tumor necrosis factor superfamily in innate immunity and inflammation.Cold Spring Harbor perspectives in biology · 2014
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Carl F Ware *Laboratory of Molecular Immunology, Infectious and Inflammatory Diseases Center, Sanford-Burnham Medical Research Institute, California, 92037, USA.
Chris Benedict *Division of Immune Regulation, La Jolla Institute for Allergy and Immunology, California, 92037, USA.
La Jolla Institute for Immunology · USSanford Burnham Prebys Medical Discovery Institute · US

Funding

HVEM-BTLA system in InflammationR01AI067890 · NIAID · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI WARE, CARL F · 2007 to 2016
$4.3M
Lymphotoxin alpha Beta and LIGHT cytokine systemsR37AI033068 · NIAID · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI WARE, CARL F · 2003 to 2012
$4.2M
SURFACE LYMPHOTOXIN A/B COMPLEXESR01AI033068 · NIAID · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI WARE, CARL F · 1994 to 2002
$1.0M
Self Complementary Recombinant AAV VectorsR01AI048074 · NIAID · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI MCCARTY, DOUGLAS M · 2003 to 2005
$431k
NIAID NIH HHS R01 AI033068NIAID NIH HHS R01 AI048074NIAID NIH HHS R01 AI067890NIAID NIH HHS R37 AI033068
6 · The paper itself

Abstract

B lymphocytes promote the initial innate interferon response to viral pathogens without the need for antigen receptor activation. B cell dependent IFN production requires the cytokine, lymphotoxin-β. The LTβ pathway is well known to regulate lymphoid organogenesis and homeostasis by differentiating stromal cells and macrophages. However, in response to viral pathogens these same B cell-regulated populations rapidly produce type 1 interferons. Thus, B cells act as innate effector cells via LTβ homeostatic pathways, which serve as innate host barriers to viral pathogens.

Identifiers

PMID24358807
PMCPMC3751138
OpenAlexW1989671510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.